Cost-effectiveness of Tyrosine Kinase Inhibitor Treatment Strategies for Chronic Myeloid Leukemia in Chronic Phase After Generic Entry of Imatinib in the United States

Conclusion:
When imatinib loses patent protection and its price declines, its use will be the cost-effective initial treatment strategy for CML-CP.

Source: JNCI - March 4, 2016 Category: Cancer & Oncology Authors: Padula, W. V., Larson, R. A., Dusetzina, S. B., Apperley, J. F., Hehlmann, R., Baccarani, M., Eigendorff, E., Guilhot, J., Guilhot, F., Hehlmann, R., Mahon, F.-X., Martinelli, G., Mayer, J., Müller, M. C., Niederwieser, D., Saussele, S., Schiffer, Tags: Article Source Type: research